S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
NASDAQ:GPCR

Structure Therapeutics (GPCR) Stock Price, News & Analysis

$36.36
+0.18 (+0.50%)
(As of 04/19/2024 ET)
Today's Range
$35.70
$37.47
50-Day Range
$33.90
$49.00
52-Week Range
$21.79
$75.02
Volume
383,323 shs
Average Volume
576,817 shs
Market Capitalization
$1.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$85.71

Structure Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
135.7% Upside
$85.71 Price Target
Short Interest
Bearish
9.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Structure Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.98) to ($0.68) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.66 out of 5 stars

Medical Sector

645th out of 911 stocks

Pharmaceutical Preparations Industry

277th out of 411 stocks

GPCR stock logo

About Structure Therapeutics Stock (NASDAQ:GPCR)

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

GPCR Stock Price History

GPCR Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Structure Therapeutics Inc. (GPCR)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
GPCR Dec 2024 50.000 call
GPCR Sep 2024 30.000 put
GPCR May 2024 30.000 put
GPCR Apr 2024 30.000 put
GPCR Mar 2024 40.000 put
GPCR Mar 2024 60.000 call
Baron Opportunity Fund Q4 2023 Shareholder Letter
See More Headlines
Receive GPCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/08/2024
Today
4/19/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GPCR
Fax
N/A
Employees
93
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$85.71
High Stock Price Target
$97.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+136.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-89,620,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.77 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.69 billion
Optionable
Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Raymond C. Stevens Ph.D. (Age 60)
    CEO & Director
    Comp: $747.33k
  • Dr. Yingli Ma Ph.D. (Age 50)
    Chief Technology Officer
    Comp: $497.58k
  • Dr. Mark A. Bach M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $628.37k
  • Mr. Jun S. Yoon (Age 46)
    Co- Founder, CFO & Secretary
  • Dr. Xichen Lin Ph.D. (Age 50)
    Chief Scientific Officer
  • Mr. Tony Peng
    Senior Vice President of Legal
  • Mr. Bob Gatmaitan
    Senior Vice President of People
  • Dr. Hui Lei Ph.D.
    Senior Vice President of Chemistry
  • Dr. Fang Zhang Ph.D.
    Executive VP & Head of Biology
  • Ms. Lani Ibarra
    Senior Vice President of Clinical Development Operations

GPCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Structure Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GPCR shares.
View GPCR analyst ratings
or view top-rated stocks.

What is Structure Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued 12 month price objectives for Structure Therapeutics' stock. Their GPCR share price targets range from $65.00 to $97.00. On average, they expect the company's stock price to reach $85.71 in the next twelve months. This suggests a possible upside of 135.7% from the stock's current price.
View analysts price targets for GPCR
or view top-rated stocks among Wall Street analysts.

How have GPCR shares performed in 2024?

Structure Therapeutics' stock was trading at $40.76 at the beginning of 2024. Since then, GPCR stock has decreased by 10.8% and is now trading at $36.36.
View the best growth stocks for 2024 here
.

Are investors shorting Structure Therapeutics?

Structure Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,740,000 shares, an increase of 15.4% from the March 15th total of 3,240,000 shares. Based on an average daily volume of 584,800 shares, the short-interest ratio is currently 6.4 days. Approximately 9.0% of the shares of the stock are sold short.
View Structure Therapeutics' Short Interest
.

When is Structure Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GPCR earnings forecast
.

How were Structure Therapeutics' earnings last quarter?

Structure Therapeutics Inc. (NASDAQ:GPCR) posted its quarterly earnings data on Friday, March, 8th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04.

What ETFs hold Structure Therapeutics' stock?

ETFs with the largest weight of Structure Therapeutics (NASDAQ:GPCR) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ).Fidelity Disruptive Medicine ETF (FMED).

When did Structure Therapeutics IPO?

Structure Therapeutics (GPCR) raised $150 million in an initial public offering (IPO) on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share.

Who are Structure Therapeutics' major shareholders?

Structure Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.10%) and TrueMark Investments LLC (0.06%).

How do I buy shares of Structure Therapeutics?

Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GPCR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners